Short Interest in Defiance Daily Target 2X Long IREN ETF (NYSEARCA:IRE) Increases By 131.3%

Defiance Daily Target 2X Long IREN ETF (NYSEARCA:IRE) was the target of a large increase in short interest in July. As of July 15th, there was short interest totaling 3,421,148 shares, an increase of 131.3% from the June 30th total of 1,479,320 shares. Based on an average daily volume of 7,517,193 shares, the short-interest ratio is currently 0.5 days. Approximately 14.6% of the shares of the stock are short sold.

Institutional Trading of Defiance Daily Target 2X Long IREN ETF

An institutional investor recently bought a new position in Defiance Daily Target 2X Long IREN ETF stock. StoneX Group Inc. acquired a new position in shares of Defiance Daily Target 2X Long IREN ETF (NYSEARCA:IRE) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 85,543 shares of the company’s stock, valued at approximately $508,000. Hedge funds and other institutional investors own 0.95% of the company’s stock.

Defiance Daily Target 2X Long IREN ETF Stock Performance

IRE stock traded up $3.52 on Thursday, reaching $9.42. The company had a trading volume of 13,966,030 shares, compared to its average volume of 6,326,938. The firm’s fifty day moving average price is $21.55. Defiance Daily Target 2X Long IREN ETF has a 1 year low of $5.70 and a 1 year high of $124.68.

iShares MSCI Ireland ETF (NYSEARCA: IRE) is an exchange-traded fund managed by BlackRock’s iShares business that provides investors with targeted exposure to Irish equities. Listed on the NYSE Arca, the fund is designed to reflect the performance of an investment benchmark composed of companies domiciled in or with significant exposure to Ireland. It offers a single-ticket way to access the Irish equity market within a U.S.-listed vehicle.

The ETF holds a portfolio of Irish companies spanning multiple sectors, giving investors exposure to the country’s prominent industries such as financials, consumer goods and services, industrials, and healthcare.